Sergliflozin etabonate is a SGLT-2 inhibitor potentially for the treatment of type 2 diabetes and obesity References: Hussey EK, Dobbins RL, Stoltz RR, Stockman NL, O'Connor-Semmes RL, Kapur A, Murray SC, Layko D, Nunez DJ. Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study. J Clin Pharmacol. 2010 Jun;50(6):636-46. doi: 10.1177/0091270009352185. PubMed PMID: 20200268.

纯度：≥98%

CAS：408504-26-7